126 related articles for article (PubMed ID: 35636055)
1. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.
Tashakori M; Wang W; Kadia TM; Daver NG; Montalban-Bravo G; Loghavi S; Wang SA; Medeiros LJ; Ravandi F; Khoury JD
Leuk Res; 2022 Jul; 118():106860. PubMed ID: 35636055
[TBL] [Abstract][Full Text] [Related]
2. Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases.
Reichard KK; Tefferi A; Abdelmagid M; Orazi A; Alexandres C; Haack J; Greipp PT
Blood Cancer J; 2022 Nov; 12(11):147. PubMed ID: 36323674
[TBL] [Abstract][Full Text] [Related]
3. [Molecular pathogenesis and therapeutic targets in acute erythroid leukemia].
Takeda J
Rinsho Ketsueki; 2022; 63(2):121-133. PubMed ID: 35264503
[TBL] [Abstract][Full Text] [Related]
4. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker H; Pfeifer D; Ihorst G; Pantic M; Wehrle J; Rüter BH; Bullinger L; Hackanson B; Germing U; Kuendgen A; Platzbecker U; Döhner K; Ganser A; Hagemeijer A; Wijermans PW; Döhner H; Duyster J; Lübbert M
Ann Hematol; 2020 Jul; 99(7):1551-1560. PubMed ID: 32504186
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
6. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.
Liu W; Hasserjian RP; Hu Y; Zhang L; Miranda RN; Medeiros LJ; Wang SA
Mod Pathol; 2011 Mar; 24(3):375-83. PubMed ID: 21102413
[TBL] [Abstract][Full Text] [Related]
7. More than 1
Montalban-Bravo G; Benton CB; Wang SA; Ravandi F; Kadia T; Cortes J; Daver N; Takahashi K; DiNardo C; Jabbour E; Borthakur G; Konopleva M; Pierce S; Bueso-Ramos C; Patel K; Kornblau S; Kantarjian H; Young KH; Garcia-Manero G; Andreeff M
Blood; 2017 May; 129(18):2584-2587. PubMed ID: 28246192
[No Abstract] [Full Text] [Related]
8. Acute leukaemia with a pure erythroid phenotype: under-recognized morphological and cytogenetic signatures associated universally with primary refractory disease and a dismal clinical outcome.
Park DC; Ozkaya N; Lovitch SB
Histopathology; 2017 Aug; 71(2):316-321. PubMed ID: 28261852
[TBL] [Abstract][Full Text] [Related]
9. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
10. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
Zhang L; McGraw KL; Sallman DA; List AF
Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
[TBL] [Abstract][Full Text] [Related]
11. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
Rücker FG; Schlenk RF; Bullinger L; Kayser S; Teleanu V; Kett H; Habdank M; Kugler CM; Holzmann K; Gaidzik VI; Paschka P; Held G; von Lilienfeld-Toal M; Lübbert M; Fröhling S; Zenz T; Krauter J; Schlegelberger B; Ganser A; Lichter P; Döhner K; Döhner H
Blood; 2012 Mar; 119(9):2114-21. PubMed ID: 22186996
[TBL] [Abstract][Full Text] [Related]
12. The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia.
Yuan YY; Zhu HY; Wu JZ; Xia Y; Liang JH; Wu W; Cao L; Wang L; Fan L; Li JY; Xu W
Genes Chromosomes Cancer; 2019 Jan; 58(1):43-51. PubMed ID: 30350431
[TBL] [Abstract][Full Text] [Related]
13. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
14. A dominant-negative effect drives selection of
Boettcher S; Miller PG; Sharma R; McConkey M; Leventhal M; Krivtsov AV; Giacomelli AO; Wong W; Kim J; Chao S; Kurppa KJ; Yang X; Milenkowic K; Piccioni F; Root DE; Rücker FG; Flamand Y; Neuberg D; Lindsley RC; Jänne PA; Hahn WC; Jacks T; Döhner H; Armstrong SA; Ebert BL
Science; 2019 Aug; 365(6453):599-604. PubMed ID: 31395785
[No Abstract] [Full Text] [Related]
15. Impact of
Firtina S; Erbilgin Y; Hatirnaz Ng O; Karaman S; Karakas Z; Celkan TT; Gelen SA; Yildirmak Y; Ozbek U; Sayitoglu M
Scand J Clin Lab Invest; 2023 May; 83(3):187-193. PubMed ID: 37029683
[TBL] [Abstract][Full Text] [Related]
16. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.
Yoshizato T; Nannya Y; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Suzuki H; Nagata Y; Sato Y; Kakiuchi N; Matsuo K; Onizuka M; Kataoka K; Chiba K; Tanaka H; Ueno H; Nakagawa MM; Przychodzen B; Haferlach C; Kern W; Aoki K; Itonaga H; Kanda Y; Sekeres MA; Maciejewski JP; Haferlach T; Miyazaki Y; Horibe K; Sanada M; Miyano S; Makishima H; Ogawa S
Blood; 2017 Apr; 129(17):2347-2358. PubMed ID: 28223278
[TBL] [Abstract][Full Text] [Related]
17. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
18. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
Leung GMK; Zhang C; Ng NKL; Yang N; Lam SSY; Au CH; Chan TL; Ma ESK; Tsui SP; Ip HW; So JCC; Ng MHL; Cheng KCK; Wong KF; Siu LLP; Yip SF; Lin SY; Lau JSM; Luk TH; Lee HKK; Lau CK; Kho B; Kwong YL; Leung AYH
Am J Hematol; 2019 Jun; 94(6):650-657. PubMed ID: 30900772
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutations in older adults with acute myeloid leukemia.
Yanada M; Yamamoto Y; Iba S; Okamoto A; Inaguma Y; Tokuda M; Morishima S; Kanie T; Mizuta S; Akatsuka Y; Okamoto M; Emi N
Int J Hematol; 2016 Apr; 103(4):429-35. PubMed ID: 26781615
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]